Diarrhea-predominant irritable bowel syndrome: Diagnosis, etiology, and new treatment considerations
Authors:
- 1 July 2016
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of the American Association of Nurse Practitioners
- Vol. 28 (7) , 393-404
Abstract
Sorder that has a negative impact on patient-related quality of life. Genetic factors, psychosociologic factors, alterations in the gut microbiota, and changes in immune, motor, and sensory responses to various stimuli all may be involved in the development of IBS. While pharmacologic therapies for IBS-D have historically been limited (e.g., alosetron), newer therapies (eluxadoline and rifaximin), both approved in the United States in 2015, may be considered for appropriate patients for the management of IBS-D. Implications for practice: Nurse practitioners play an important role in the diagnosis, care, and management of patients with IBS-D. The goals of therapy should be to reach a correct diagnosis before initiating therapy, provide reassurance to the patient, educate the patient on potential treatment options, improve IBS-D symptoms, minimize risk of harm with treatment, and maximize patient-related quality of life. The authors present a treatment algorithm to guide nurse practitioners on the management of patients with IBS-D....Keywords
Funding Information
- Salix Pharmaceuticals
This publication has 49 references indexed in Scilit:
- Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadolineThe Journal of Clinical Pharmacology, 2015
- Eluxadoline Benefits Patients With Irritable Bowel Syndrome With Diarrhea in a Phase 2 StudyGastroenterology, 2013
- Peripheral Mechanisms in Irritable Bowel SyndromeNew England Journal of Medicine, 2012
- Irritable Bowel Syndrome: Methods, Mechanisms, and Pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndromeAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2012
- A Very Low-Carbohydrate Diet Improves Symptoms and Quality of Life in Diarrhea-Predominant Irritable Bowel SyndromeClinical Gastroenterology and Hepatology, 2009
- A Focus Group Assessment of Patient Perspectives on Irritable Bowel Syndrome and Illness SeverityDigestive Diseases and Sciences, 2009
- Incidence of Ischemic Colitis and Serious Complications of Constipation Among Patients Using Alosetron: Systematic Review of Clinical Trials and Post-Marketing Surveillance DataAmerican Journal of Gastroenterology, 2006
- Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trialGut, 2004
- Irritable bowel syndrome – an evidence‐based approach to diagnosisAlimentary Pharmacology & Therapeutics, 2004
- AGA technical review on irritable bowel syndromeGastroenterology, 2002